Sign-up to receive news as it is released.

Archives: Search / 2017 / 2016 / 2015

201420122011

2014 Archives

Dec 1, 2014
-- Results Confirm Favorable Safety Profile of Two High Doses of Aramchol --

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment...

More
Nov 13, 2014

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the...

More
Nov 12, 2014
-- Conference Call and Webcast Today at 8:30 a.m. EST/5:30 a.m. PST --

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment...

More
Nov 5, 2014

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the...

More
Nov 5, 2014

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment...

More
Sep 29, 2014

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the...

More
Sep 23, 2014

Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of...

More
Sep 2, 2014

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment...

More
Jul 25, 2014
-- Conference Call and Webcast Today at 8:30 a.m. EDT/5:30 a.m. PDT --

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (Galmed), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of...

More
Jul 22, 2014

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment...

More
Jul 21, 2014

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment...

More
Jul 8, 2014

Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed") today announced the recent publication of the results of its Phase IIa clinical trial of aramchol in the peer-reviewed Clinical...

More
Jun 9, 2014

TEL AVIV, Israel, Jun 09, 2014 (GLOBE NEWSWIRE via COMTEX) -- Galmed Pharmaceuticals Ltd. GLMD +0.79% ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and...

More
Jun 4, 2014

TEL AVIV, Israel, June 4, 2014 (GLOBE NEWSWIRE) -- Galmed Pharmaceuticals Ltd. (GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a...

More
May 15, 2014

Galmed Pharmaceuticals Ltd. (Nasdaq:GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of...

More
Apr 28, 2014

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment...

More
Mar 18, 2014

Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed") today announced the closing of its initial public offering of 3,263,010 ordinary shares at a...

More
Mar 12, 2014

Galmed Pharmaceuticals Ltd. ("Galmed") today announced the pricing of its initial public offering of 2,837,400 ordinary shares at a public...

More
 

print email rss